February 25th 2021
John V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.
February 23rd 2021
John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer.
June 2nd 2017
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.
April 14th 2017
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.
April 7th 2017
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.